Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
Granted 7 Jan 2014 · 16 office actions
Current assignee: Chugai Pharmaceutical Co., Ltd. (Roche) · originally Roche
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Shinya Ishii, Atsuhiko Maeda, Takashi Nakai, Tomoyuki Igawa · Examiner: James Rogers
Life of the patent
29 dated eventsAbstract
The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
Claims
17 · 8 independent · depth 2Classifications
8 codes- A61K39/00
- A61K39/395
- C07K16/00
Claim changes
SoonSee which claims were amended, added or cancelled during examination, with every added and removed word marked.
The published claims of this patent are not paired with the granted ones in what we hold.
File wrapper
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockTerm & fees
See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.
Log in to unlockPriority chain
1 priority documents›Priority documents — 1
| Type | Document | Date |
|---|---|---|
| related publication | US 20130011866 A1 | 10 Jan 2013 |
Validity challenges
See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.
Log in to unlockCitations
See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.
Log in to unlock